Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. - Wikidata - awgldk - TriplyDB

Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome.

Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome.

http://www.wikidata.org/entity/Q46402910

about

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes Extended flow cytometry characterization of normal bone marrow progenitor cells by simultaneous detection of aldehyde dehydrogenase and early hematopoietic antigens: implication for erythroid differentiation studies.The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure Recent advancements of flow cytometry: new applications in hematology and oncology.Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Myelodysplastic syndromes: diagnosis and staging.Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study.Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia.Role of flow cytometry in myelodysplastic syndromes: diagnosis, classification, prognosis and response assessment.Importance of classical morphology in the diagnosis of myelodysplastic syndrome.Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes.Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells.Assessment of erythroid dysplasia by "difference from normal" in routine clinical flow cytometry workup.Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome.CD71 (transferrin receptor): an effective marker for erythroid precursors in bone marrow biopsy specimens.Molecular pathways of early CD105-positive erythroid cells as compared with CD34-positive common precursor cells by flow cytometric cell-sorting and gene expression profiling.Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.Significance of CD71 expression by flow cytometry in diagnosis of acute leukemia.Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome.Assessment of normal erythropoiesis by flow cytometry: important considerations for specimen preparation.Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.The Use of Flow Cytometry in Myelodysplastic Syndromes: A Review.Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes.Immunophenotypic profile of nucleated erythroid progenitors during maturation in regenerating bone marrow.Distinct neutrophil subpopulations phenotype by flow cytometry in myelodysplastic syndromes.Value of Quantitative assessment of Myeloid Nuclear Differentiation Antigen expression and other flow cytometric parameters in the diagnosis of Myelodysplastic syndrome.High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes.Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms. British Committee for Standards in Haematology.Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts

P2860

Q24604581-3F8F1B4A-4A82-42F3-837B-81D46ABB2E90 Q26742112-EAC932D9-0263-4DD0-8CFD-BC97AD429DA3 Q33338664-B42C86F4-9B2A-4EDD-880D-9B24989C5464 Q33829778-8003F863-A310-4EB0-B1F6-D2A0A46A8642 Q35059549-D73FFE33-5A24-4A65-AD50-FC51B99B511C Q35146272-676640DA-8571-44E8-83E6-6DF4D9235F28 Q36133023-E436D4B6-E412-4194-AE65-4A977A5C6DB3 Q37263146-131BE3BE-D22A-4944-8CF0-687940E97A8A Q37277991-0127B5CA-4004-48F8-9CDF-CA3B3D4B946E Q37284393-46F4AD81-3084-4A73-B993-30250BB54444 Q37850824-9AA370A7-CB9E-4F3E-87BC-159CA99945F2 Q37889846-DBBAA460-9581-4462-BFB9-50706E034BD7 Q38117677-FDEAFC7E-EB6E-4BF8-9C70-6847441DA214 Q38471249-194ACF44-E9CD-4E8D-B153-DC40CBAE73E1 Q38908087-629B75FD-49E4-4402-8AC4-0C72056C8233 Q39272518-161C9FDC-5B3C-4598-B89C-F173F39431DB Q39361802-76CF31A4-2C63-4E12-A3E3-787742D33D54 Q39968886-6CB6B582-B835-4EB6-A700-F63F4515C8F5 Q41530060-8F56F5F4-8ECB-4552-89F5-D2DCD4D084F3 Q41711144-9631CD7C-863F-4FCE-B15D-702A49E4A3C6 Q42638915-D96F5172-297F-4083-A25B-737043DA49B3 Q42660774-77EBA8FE-4E53-42F1-BA92-23EAAB82F3F6 Q42662183-C350F60A-94E8-48AE-A699-6A6DB0BD61A7 Q42934778-72BDD2FF-34F2-4578-8AF3-50EDF0C9C94D Q43023440-367F135A-6710-4EFA-8973-BD49551CC346 Q44306106-083FD486-26D9-4F7E-A361-DEC0630EE49B Q46351056-94F7AB29-CF1E-4902-9A50-27DDE0501B45 Q46960830-DAA3DE81-6C9B-4786-9EAD-280141899771 Q46967957-BB8FCAAC-DA8A-42ED-8F57-BD649E657BC5 Q47124670-459BA9C6-8EAE-4F3C-8C93-52D6A2523E4C Q47145316-2408E7A8-7CFC-4572-979C-C0142861A5AF Q50523970-A2CD798A-B9FB-45F5-82BF-8D2CA4F0A7A1 Q50756735-C6DCA4D0-EC81-45A7-9395-FD8826B91186 Q51763561-D6B08FD2-EBA0-46C8-A610-FE6E0AFE6AC4 Q52886979-2965F625-5C10-4883-94A8-0878D859A0C9 Q53087747-BF3D0FDC-A8AC-40A3-913F-9C93BED9E42A Q53237344-2820E8B0-59FB-4184-AB5C-093FE19677C0 Q53600589-F64FB405-44A8-4B09-9BC3-169253EC2875 Q58793895-E55E3802-4E56-44A0-9D3C-A1566D572B58

P2860

Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome.

http://www.wikidata.org/entity/Q46402910

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Flow cytometry evaluation of e ...... with myelodysplastic syndrome.

@en

Flow cytometry evaluation of e ...... with myelodysplastic syndrome.

@nl

type

label

Flow cytometry evaluation of e ...... with myelodysplastic syndrome.

@en

Flow cytometry evaluation of e ...... with myelodysplastic syndrome.

@nl

prefLabel

Flow cytometry evaluation of e ...... with myelodysplastic syndrome.

@en

Flow cytometry evaluation of e ...... with myelodysplastic syndrome.

@nl

P1433

Q46402910-0E1E3B6B-6345-469D-8226-D4807099CC0D

P1476

Q46402910-6D4D6CA0-4B62-41C5-9068-4D187C55326F

P2093

Q46402910-0D02C160-7A38-4EA4-B9FC-9846340EDAAB

Q46402910-490F72AF-D9D6-428F-ACA9-209715329708

Q46402910-6C0B9FE4-680C-4723-ADB8-1A6BB1D83813

Q46402910-6C8D74BA-9498-4D1B-A1D0-94E8106D98FA

Q46402910-BE7594FB-3AD2-4A0D-AE75-9674F188122F

Q46402910-D69530A0-0B02-4C22-8D80-6FA524FC76E9

Q46402910-D7382F80-5136-4F5C-B70D-6E831B81B921

Q46402910-DC0F04D3-69F9-43B0-B452-C29DE83D3044

Q46402910-DE6E90ED-5E0D-45D2-9BD9-B6FBF6432403

Q46402910-E972D3B3-5D38-4310-A101-B8CF211A61D6

P2860

Q46402910-04DB2A15-4AE4-4069-878C-CD719E53B1E2

Q46402910-163FE6EA-EC14-41D5-8EEF-FCB97D1584C3

Q46402910-1906F99D-0B4B-48AF-A9BA-72C77388AECF

Q46402910-3321A41A-AD9F-4D2D-A76D-8B4C78534F64

Q46402910-33F3F5B0-DE86-48CF-9C31-18ACD4464615

Q46402910-5FEDF63F-2642-42D6-ADD5-330CFA06B2CC

Q46402910-6979087E-8FA0-4CFC-B71C-3CEEA225E6F1

Q46402910-7A679378-3362-4032-83C3-6538988517AD

Q46402910-9FC46782-817E-4FC1-8659-6B8A22546AC2

Q46402910-AFF7F6E3-382C-424B-9A17-75FB3884505D

P2888

Q46402910-F41B59F5-FA85-4215-9B56-97435E8D1AD8

P304

Q46402910-957E9DC0-8858-42F0-9B32-A85C070185B8

P31

Q46402910-E5AB5064-7096-4E95-99A6-D037E925FEA1

P356

Q46402910-031F946C-25BD-4C15-A29E-B8D9AA2746B2

P433

Q46402910-427BCE85-4C56-4EE7-9CAF-4190FFBA7D52

P478

Q46402910-9520105F-6700-42D8-AECF-0A932995E302

P50

Q46402910-36E3789A-2131-4573-B192-8D8770302B5D

P577

Q46402910-5BC8DC60-12BD-4758-B641-938919AE1EA3

P5875

Q46402910-BE3AC9ED-C2F7-4C1A-9EF9-9F3EB6380EE1

P698

Q46402910-44F38E45-68E5-4926-9AE5-CA5C663E9EEC

P356

P1433

P1476

Flow cytometry evaluation of e ...... with myelodysplastic syndrome

@en

P2093

Cazzola M

http://www.w3.org/2001/XMLSchema#string

Della Porta MG

http://www.w3.org/2001/XMLSchema#string

Invernizzi R

http://www.w3.org/2001/XMLSchema#string

Lazzarino M

http://www.w3.org/2001/XMLSchema#string

Lunghi M

http://www.w3.org/2001/XMLSchema#string

Maffioli M

http://www.w3.org/2001/XMLSchema#string

Malcovati L

http://www.w3.org/2001/XMLSchema#string

Pascutto C

http://www.w3.org/2001/XMLSchema#string

Travaglino E

http://www.w3.org/2001/XMLSchema#string

Vanelli L

http://www.w3.org/2001/XMLSchema#string

P2860

The World Health Organization (WHO) classification of the myeloid neoplasms

Procedural guidelines for performing immunophenotyping by flow cytometry

Proposals for the classification of the myelodysplastic syndromes

Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. European Working Group on Clinical Cell Analysis.

Myelodysplasia--therapeutic response to novel therapy and the need for new diagnostic groups.

Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications

Immunophenotypic clustering of myelodysplastic syndromes.

U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures.

Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.

Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.

P2888

P304

776-783

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2403680

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Bernasconi

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7946955

http://www.w3.org/2001/XMLSchema#string

P698

15789068

http://www.w3.org/2001/XMLSchema#string